Understand the source comparison
Tesofensine Peptide vs GLP-1 Agonists: Mechanism Comparison
Primary Mechanism Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin). Central appetite regulation GLP-1 receptor agonism. Slows gastric emptying, peripheral satiety signaling Tesofensine works in the brain; semaglutide works in the gut
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary Mechanism
- Triple monoamine reuptake inhibition (dopamine, norepinephrine, serotonin). Central appetite regulation
- GLP-1 receptor agonism. Slows gastric emptying, peripheral satiety signaling
- Tesofensine works in the brain; semaglutide works in the gut and pancreas
- Weight Loss (24-week mean)
- 10.6% body weight reduction at 0.5mg daily (Phase IIb trial)
- 14.9% body weight reduction at 2.4mg weekly (STEP-1 trial)
- Comparable magnitude, different timelines. GLP-1 agents show slightly higher efficacy in head-to-head comparison
- Dosing Frequency
- Once daily (8-day half-life)
- Once weekly (5-day half-life)
- Tesofensine requires daily adherence; semaglutide offers weekly convenience
- Side Effect Profile
- Insomnia, dry mouth, nausea, increased heart rate (5–10 bpm elevation in 30% of patients)
- Nausea, vomiting, diarrhea (30–45% during titration); GI effects resolve over 4–8 weeks
- Tesofensine carries cardiovascular monitoring requirements due to sympathomimetic effects; GLP-1 agonists are primarily GI-limited
- Regulatory Status
- Phase IIb completed (2008); no FDA approval; available as research compound only
- FDA-approved for chronic weight management (Wegovy 2021)
- Semaglutide is a prescription medication; tesofensine remains investigational
- Professional Assessment
- Tesofensine shows strong efficacy in controlled trials but lacks the long-term safety data and regulatory approval that make GLP-1 agonists the current standard of care. The cardiovascular signal (heart rate elevation) limits its use in patients with pre-existing hypertension or arrhythmia.
- For research applications exploring monoamine-mediated appetite regulation, tesofensine offers a validated tool. For clinical weight management, GLP-1 agonists remain the evidence-based choice with established safety profiles and FDA oversight.